Healthcare Wrap: BLS Leads Gains as Trials, Funding and Sales Updates Drive Trading

• Actinogen Medical rose 20.45% after securing A$4.77 million in underwriting before November Alzheimer’s results.
• Ceretas and Memphasys each gained 20% as Ceretas funded its next trial and Memphasys began Felix sales in Turkey.
• BLS Pharmaceuticals surged 23.91% for the week after reporting 161% revenue growth and a $50 million German contract.
• Artrya fell 12% despite US contracts and an $80 million raise, while Microba posted higher losses despite strong core testing growth.